| Dr Patrick F Walsh, DO | |
|
510 Butler Ave, Martinsburg, WV 25405-9990 | |
| (304) 263-0811 | |
| Not Available |
| Full Name | Dr Patrick F Walsh |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Critical Care Medicine |
| Location | 510 Butler Ave, Martinsburg, West Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780624957 | NPI | - | NPPES |
| Entity Name | Winchester Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679711261 PECOS PAC ID: 0244134021 Enrollment ID: O20031124000061 |
News Archive
A new study of attitudes about health care costs reveals that an overwhelming majority of U.S. physicians feel a responsibility to address costs, but prioritize their obligations to patients' best interests over cost concerns. Results of the random survey of 2,500 U.S. physicians are published in this week's Journal of the American Medical Association.
Improvements in motor vehicle safety have been recognized by the Centers for Disease Control and Prevention as ranking among the 20th century's top public health achievements, however a recent study led by researchers in the Department of Preventive Medicine and Biometrics at the Uniformed Services University of the Health Sciences seems to show that the improvements aren't benefiting all segments of the population equally.
Infection control and critical care experts at The Johns Hopkins Hospital have ordered testing for the two most common hospital superbugs for every child admitted to its pediatric intensive care unit.
Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.
› Verified 9 days ago
| Entity Name | Inova Health Care Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952320061 PECOS PAC ID: 2466351093 Enrollment ID: O20080806000696 |
News Archive
A new study of attitudes about health care costs reveals that an overwhelming majority of U.S. physicians feel a responsibility to address costs, but prioritize their obligations to patients' best interests over cost concerns. Results of the random survey of 2,500 U.S. physicians are published in this week's Journal of the American Medical Association.
Improvements in motor vehicle safety have been recognized by the Centers for Disease Control and Prevention as ranking among the 20th century's top public health achievements, however a recent study led by researchers in the Department of Preventive Medicine and Biometrics at the Uniformed Services University of the Health Sciences seems to show that the improvements aren't benefiting all segments of the population equally.
Infection control and critical care experts at The Johns Hopkins Hospital have ordered testing for the two most common hospital superbugs for every child admitted to its pediatric intensive care unit.
Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Patrick F Walsh, DO 1109 S Sleepy Creek Rd, Cross Junction, VA 22625-1966 Ph: (540) 877-1405 | Dr Patrick F Walsh, DO 510 Butler Ave, Martinsburg, WV 25405-9990 Ph: (304) 263-0811 |
News Archive
A new study of attitudes about health care costs reveals that an overwhelming majority of U.S. physicians feel a responsibility to address costs, but prioritize their obligations to patients' best interests over cost concerns. Results of the random survey of 2,500 U.S. physicians are published in this week's Journal of the American Medical Association.
Improvements in motor vehicle safety have been recognized by the Centers for Disease Control and Prevention as ranking among the 20th century's top public health achievements, however a recent study led by researchers in the Department of Preventive Medicine and Biometrics at the Uniformed Services University of the Health Sciences seems to show that the improvements aren't benefiting all segments of the population equally.
Infection control and critical care experts at The Johns Hopkins Hospital have ordered testing for the two most common hospital superbugs for every child admitted to its pediatric intensive care unit.
Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.
› Verified 9 days ago
Dr. Susila Rajakumar, M.D. Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 510 Butler Ave, Martinsburg, WV 25401 Phone: 304-263-0811 | |
Sonia Nasery, Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 1004 Sushruta Dr Ste A, Martinsburg, WV 25401 Phone: 571-502-1340 | |
Dr. Philip J A Ryan, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 176 Health Care Ln, Suite B, Martinsburg, WV 25401 Phone: 304-260-1060 Fax: 304-260-1062 | |
Samuel Ryan Morris, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 101 Marcley Dr, Martinsburg, WV 25401 Phone: 304-263-8911 Fax: 304-263-9450 | |
Dr. Pradip Chakravarti, M.D. Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 510 Butler Ave, Martinsburg, WV 25405 Phone: 304-263-0811 Fax: 304-262-1417 | |
Joyce R. Chang, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 510 Butler Ave, Martinsburg Va Medical Center, Martinsburg, WV 25405 Phone: 304-263-0811 | |
Dr. Robert E Bowen, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 Foundation Way, Suite 2400, Martinsburg, WV 25401 Phone: 304-264-9080 Fax: 304-264-9082 |